Company Overview
| Stock Name | Sinco Pharma |
|---|---|
| Stock Code | 06833 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 為中國醫藥行業第三大營銷、推廣及渠道管理服務供應商,亦是中國血漿藥品唯一相關服務供應商,為海外中小型製藥商提供綜合營銷、推廣及渠道管理服務。 |
| Listing Date | 2016-03-10 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國四川省成都市高新區天府大道北段1700號環球中心E5-1805室 |
| Business Address (Hong Kong) | 香港皇后大道中183號中遠大廈44樓4408A室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.sinco-pharm.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 0.80 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 0.0001 / shares |
| Offer Period | 2016-02-29 to 2016-03-03 |
| Global Offering Shares | 400,000,000 shares |
| HK Public Offer Shares (Initial) | 40,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 360,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,600,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 6.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 320,000,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 312.5M |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +3009% |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2012 | 2013 | 2014 | 2015-10 |
|---|---|---|---|---|
| Revenue | 26,166 | 532,480 | 950,079 | 850,795 |
| Cost of sales | -22,934 | -471,361 | -820,309 | -737,381 |
| Gross profit | 3,232 | 61,119 | 129,770 | 113,414 |
| Other income and gains, net | 215 | 4,920 | 2,295 | 534 |
| Selling and distribution expenses | -225 | -2,358 | -6,792 | -4,186 |
| Administrative expenses | -2,673 | -9,866 | -17,520 | -29,838 |
| Operating profit | 529 | 51,981 | 100,038 | 69,453 |
| Net finance costs | 0 | -1,062 | -6,226 | -6,054 |
| Profit before tax | 529 | 50,919 | 93,812 | 63,399 |
| Income tax expense | -253 | -7,932 | -13,683 | -12,321 |
| Profit for the year | 276 | 42,987 | 80,129 | 51,078 |
| Profit attributable to owners | 138 | 36,539 | 69,367 | 51,080 |
Balance Sheet
| Item | 2012 | 2013 | 2014 | 2015-10 |
|---|---|---|---|---|
| Cash and cash equivalents | 26,679 | 27,851 | 58,280 | 42,013 |
| Trade and bills receivables | 0 | 11,402 | 50,060 | 0 |
| Inventories | 82,860 | 59,319 | 30,224 | 32,836 |
| Total current assets | 112,929 | 273,193 | 288,092 | 173,634 |
| Total assets | 122,766 | 376,845 | 441,214 | 418,051 |
| Total current liabilities | 117,697 | 328,489 | 317,729 | 242,860 |
| Total liabilities | 117,697 | 328,489 | 317,729 | 242,860 |
| Total equity | 5,069 | 48,356 | 123,485 | 175,191 |
| Equity attributable to owners | 4,308 | 40,847 | 105,214 | 174,894 |
| Interest-bearing borrowings | 0 | 51,515 | 91,788 | 92,806 |
Cash Flow Statement
| Item | 2012 | 2013 | 2014 | 2015-10 |
|---|---|---|---|---|
| Net cash from operating activities | -889 | 77,899 | 53,137 | 25,491 |
| Net cash from investing activities | -9,596 | -89,821 | -41,628 | -45,847 |
| Net cash from financing activities | 40,400 | 26,247 | 14,301 | 9,904 |
| Net increase in cash | 29,915 | 14,325 | 25,810 | -10,452 |
| Depreciation of PP&E | 195 | 1,006 | 1,878 | 4,045 |
| Amortisation of intangible assets | 0 | 0 | 0 | 4,204 |
| Purchase of PP&E | -9,596 | -50,013 | -33,447 | -8,245 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 0.8 |
|---|---|
| First Day Open | HK$ 0.9 |
| First Day Change | -73.50% |
| First Day Volume | 149292000.0 |
| First Day Turnover | 131237000.0 |
| Use of Proceeds | 1、約45%(約146.2百萬港元)將用于(i)收購新產品的銷售及經銷權;及(ii)收購醫藥行業具備專有知識產權或增長潛力的企業;
2、約33%(約107.2百萬港元)將不可撤回地用作償還本集團尚未償還的部分貸款及銀行貿易信貸;
3、約14%(約45.5百萬港元)將用于在四川雙流保稅區開發冷鏈設施及研發基地,預期冷鏈設施竣工后會成為中國西南地區最大的冷鏈設施之一;
4、約8%(約26.0百萬港元)將用作營運資金及其他一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Overall Coordinators (1)
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Bookrunners (1)
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Joint Lead Managers (1)
CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Prestigious Leader Limited | 50,000,000 HKD | — | 3.90% | — | 6 months | 2016-09-10 |
| 2 | 四川惠丰投资发展有限责任公司 | 38,758,400 HKD | — | 3.00% | — | 6 months | 2016-09-10 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 黃祥彬 | — |
| Company Secretary | 高潁妤 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Risun持有1,050,000,000股,佔已發行股本65.625%;黃先生透過Risun持有同等權益。 |
|---|




